Standout Papers

Effects of Concomitant Cisplatin and Radiotherapy on Inoperable Non-Small-Cell Lung Cancer 1992 2026 2003 2014 977
  1. Effects of Concomitant Cisplatin and Radiotherapy on Inoperable Non-Small-Cell Lung Cancer (1992)
    C. Schaake-Koning, Walter Van den Bogaert et al. New England Journal of Medicine
  2. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. (1997)
    Harry Bartelink, F. Roelofsen et al. Journal of Clinical Oncology
  3. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival (2005)
    Howard Y. Chang, Dimitry S.A. Nuyten et al. Proceedings of the National Academy of Sciences
  4. Impact of a Higher Radiation Dose on Local Control and Survival in Breast-Conserving Therapy of Early Breast Cancer: 10-Year Results of the Randomized Boost Versus No Boost EORTC 22881-10882 Trial (2007)
    Harry Bartelink, Jean-Claude Horiot et al. Journal of Clinical Oncology
  5. Recurrence Rates after Treatment of Breast Cancer with Standard Radiotherapy with or without Additional Radiation (2001)
    Harry Bartelink, Jean-Claude Horiot et al. New England Journal of Medicine
  6. Long-Term Risk of Cardiovascular Disease in 10-Year Survivors of Breast Cancer (2007)
    Maartje J. Hooning, Akke Botma et al. JNCI Journal of the National Cancer Institute
  7. Late cardiotoxicity after treatment for Hodgkin lymphoma (2006)
    Berthe M.P. Aleman, Alexandra W. van den Belt‐Dusebout et al. Blood
  8. Quality of life of early-stage breast cancer patients treated with radical mastectomy or breast-conserving procedures: results of EORTC trial 10801 (1998)
    Desmond Curran, Neil K. Aaronson et al. European Journal of Cancer

Immediate Impact

8 by Nobel laureates 4 from Science/Nature 114 standout
Sub-graph 1 of 16

Citing Papers

Nanomedicine Tumor Targeting
2024 Standout
Breast cancer
2021 Standout
44 intermediate papers

Works of Harry Bartelink being referenced

Breast-Conserving Treatment With or Without Radiotherapy in Ductal Carcinoma In Situ: 15-Year Recurrence Rates and Outcome After a Recurrence, From the EORTC 10853 Randomized Phase III Trial
2013
The addition of a boost dose on the primary tumour bed after lumpectomy in breast conserving treatment for breast cancer. A summary of the results of EORTC 22881-10882 “boost versus no boost” trial
2008
and 31 more

Author Peers

Author Last Decade Papers Cites
Harry Bartelink 8953 6930 5168 5360 269 20.1k
Bruce G. Haffty 10489 7892 5630 2938 531 20.1k
Lawrence J. Solin 9469 6158 6063 3894 231 17.4k
Benjamin D. Smith 6832 9055 2827 3564 369 18.8k
Philip Poortmans 8585 6879 5036 4460 309 18.7k
Jay R. Harris 13608 7008 7947 2406 274 18.6k
R. Arriagada 5694 9055 2831 8904 198 17.3k
Marie Overgaard 7168 4242 3275 2569 136 12.2k
Paolo Veronesi 12459 7077 8067 3338 449 19.4k
Umberto Veronesi 20996 12099 13127 2891 402 31.3k
Sharon H. Giordano 7254 10503 2564 3973 402 20.1k

All Works

Loading papers...

Rankless by CCL
2026